Orphan drugs’ financial success raises questions
pharmaphorum
JUNE 2, 2022
In 1983, the US Congress passed the Orphan Drug Act to encourage more pharmaceutical companies to engage in R&D to develop treatments for rare diseases through the offering of financial incentives. This is why the action by the US in 1983 and subsequently the European Commission Regulation No. It is estimated that between 3.5
Let's personalize your content